Introduction: Sai Life Sciences strengthens compliance with Annual Report submission

Sai Life Sciences Limited, one of India’s leading pharmaceutical research and manufacturing companies, has filed its Annual Report for the financial year 2024-25 with both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). The disclosure has been made in compliance with Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to submit their annual report containing audited financial statements, management analysis, and governance disclosures.

This filing marks the 26th Annual Report of Sai Life Sciences, reflecting its growth, resilience, and performance in a rapidly evolving pharmaceutical sector. The company also announced that the report has been shared electronically with all shareholders who have registered their email addresses with the company, registrar, transfer agent, or depository participant. Additionally, the report is available on the company’s official website for wider investor access.

Regulatory compliance: Why SEBI mandates Annual Report submission

The Securities and Exchange Board of India (SEBI) plays a central role in protecting investor interests and ensuring transparency in the securities market. Under Regulation 34 of SEBI LODR Regulations, 2015, every listed entity must:

• Submit its annual report to the stock exchanges within the prescribed timelines.

• Send the annual report to all shareholders, preferably through electronic mode, to reduce delays and ensure wide accessibility.

• Publish the annual report on the company’s official website.

Sai Life Sciences has complied with all these obligations, demonstrating its commitment towards corporate governance and investor relations.

Highlights of Sai Life Sciences’ 26th Annual Report FY2024-25

The Annual Report FY2024-25 of Sai Life Sciences is a comprehensive document that covers financial as well as non-financial information about the company. Some of the key sections included are:

1. Board of Directors’ Report – This section provides an overview of the company’s business performance, strategies implemented during the year, corporate social responsibility (CSR) activities, and key decisions taken by the board.

2. Management Discussion and Analysis (MD&A) – The MD&A section offers detailed insights into the pharmaceutical industry landscape, challenges faced by the company, future growth opportunities, and operational performance.

3. Corporate Governance Report – In compliance with SEBI requirements, the report contains detailed disclosures on the composition of the board, independence of directors, audit committee activities, nomination and remuneration committee reports, and policies for transparency.

4. Audited Financial Statements – One of the most crucial parts of the annual report, this includes the balance sheet, profit and loss account, cash flow statements, and notes to accounts. It highlights the financial health of the company for FY2024-25.

5. Auditor’s Report – External statutory auditors provide their independent opinion on the company’s financial reporting standards and compliance with applicable laws.

6. Sustainability and CSR Initiatives – Sai Life Sciences has continued to focus on environment-friendly operations, green manufacturing practices, and healthcare-driven CSR projects to create long-term value.

Sai Life Sciences: Company background and industry relevance

Founded in 1999, Sai Life Sciences has grown into a global pharmaceutical research, development, and manufacturing company with strong presence in India and abroad. Over the years, it has built deep expertise in drug discovery, contract research, clinical development, and manufacturing of Active Pharmaceutical Ingredients (APIs).

The company partners with global biotech firms and pharmaceutical innovators to accelerate drug development, especially in therapeutic areas such as oncology, neuroscience, and infectious diseases.

Sai Life Sciences has also invested in world-class R&D facilities, green chemistry, and digital transformation initiatives, making it a trusted partner for both Indian and international pharmaceutical markets.

Performance overview for FY2024-25

While the detailed financial numbers are included in the Annual Report, Sai Life Sciences’ FY2024-25 performance reflects a combination of growth, innovation, and resilience. The pharmaceutical industry faced multiple challenges such as pricing pressures, regulatory complexities, and global supply chain disruptions. Despite this, Sai Life Sciences continued to build a robust pipeline of services and partnerships.

Key performance highlights include:

• Expansion of research collaborations with global pharma companies.

• Increase in API exports to regulated markets.

• Strengthening of compliance and quality assurance systems.

• Continued investment in green manufacturing facilities.

• Strong employee engagement and skill development programmes.

Importance for shareholders and investors

For investors, the Annual Report is more than just a compliance document – it is a comprehensive guide to understand how the company is performing, how it is governed, and what strategies it is adopting for the future.

By submitting the FY2024-25 report, Sai Life Sciences ensures that shareholders have access to transparent and reliable information about the company. This also helps analysts, institutional investors, and regulatory authorities assess the company’s performance, risks, and opportunities.

Corporate governance and transparency

In today’s corporate environment, good governance and transparency are as important as financial performance. Sai Life Sciences, through its Annual Report, has showcased:

• A balanced and diverse board structure.

• Strong emphasis on independent directors and ethical decision-making.

• Transparent remuneration policies and disclosures.

• Regular audit committee reviews for compliance and accountability.

Such measures reinforce investor confidence and build the company’s reputation in the capital markets.

Accessing the Annual Report

The company has made the 26th Annual Report FY2024-25 available through multiple channels:

1. Electronic circulation – Sent to all members who have registered their email addresses with the company, RTA, or depository participants.

2. Company website – The report can be downloaded in PDF format from Sai Life Sciences’ official investor relations page.

3. Stock Exchange portals – The report has been uploaded to the NSE and BSE portals for public access.

This ensures seamless access for investors and stakeholders across geographies.

Conclusion: A step towards stronger investor trust

The filing of the Annual Report FY2024-25 by Sai Life Sciences marks another step in the company’s journey towards stronger corporate governance, transparent disclosures, and shareholder engagement.

By complying with SEBI’s Regulation 34 requirements, the company has reinforced its commitment to responsible business practices, ensuring that all stakeholders are well-informed about its progress, performance, and future outlook.

As Sai Life Sciences continues to expand its global footprint in the pharmaceutical industry, the Annual Report serves as a key communication tool, bridging the gap between management and investors, while setting the tone for future growth and innovation.

The Upcoming IPOs in this week and coming weeks are Mangal Electrical Industries, LGT Business Connextions, Vikram Solar, Gem Aromatics, Studio LSD, Shreeji Shipping Global, Patel Retail.

The Current active IPO are Regaal Resources, Mahendra Realtors and Infrastructure.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.